787596-41-2 Usage
Uses
Used in Pharmaceutical Industry:
METHYL 2-CHLORO-3-METHYLISONICOTINATE is used as a key intermediate in the synthesis of new drugs for the treatment of neurological disorders and cancer. Its unique chemical structure allows for the development of innovative therapeutic agents with potential efficacy in addressing unmet medical needs.
Used in Agrochemical Industry:
In the agrochemical sector, METHYL 2-CHLORO-3-METHYLISONICOTINATE is utilized as a building block for the synthesis of various agrochemicals, contributing to the development of effective pest control agents and crop protection products.
Used in Organic Synthesis:
METHYL 2-CHLORO-3-METHYLISONICOTINATE is employed as an important intermediate in organic synthesis, enabling the creation of a wide range of organic compounds for diverse applications in various industries, including chemical manufacturing, materials science, and research and development.
Check Digit Verification of cas no
The CAS Registry Mumber 787596-41-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,8,7,5,9 and 6 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 787596-41:
(8*7)+(7*8)+(6*7)+(5*5)+(4*9)+(3*6)+(2*4)+(1*1)=242
242 % 10 = 2
So 787596-41-2 is a valid CAS Registry Number.
InChI:InChI=1/C8H8ClNO2/c1-5-6(8(11)12-2)3-4-10-7(5)9/h3-4H,1-2H3
787596-41-2Relevant academic research and scientific papers
SUBSTITUTED BENZENE COMPOUNDS
-
, (2012/11/06)
The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES
-
Page/Page column 58-59, (2010/11/27)
The present invention relates to a compound represented by Formula [I] or a pharmaceutically acceptable salt or ester thereof: wherein: X1, X2, X3, and X4, which may be identical or different, are each C or N, provided that none to two of X1, X2, X3, and X4 is/are N; Y is CH or N; R1, R1', R2, R2', R3, R3', R4, and R4', which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R5 is a hydrogen atom or a methyl group; R6 and R7, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R8 and R8', which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R9 is an aryl group or a heteroaryl group which may be substituted; and n is an integer from 1 to 3, and a PLK1 inhibitor or an anticancer agent containing the same.
